OpenURL Connection Search

Select item for more details and to access through your institution.

SPECT Imaging of SST2-Expressing Tumors with 99m Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.
Published in:
Pharmaceuticals (14248247), 2021, v. 14, n. 4, p. 300, doi. 10.3390/ph14040300
By:
- Gaonkar, Raghuvir Haridas;
- Wiesmann, Fabius;
- Del Pozzo, Luigi;
- McDougall, Lisa;
- Zanger, Sandra;
- Mikołajczak, Renata;
- Mansi, Rosalba;
- Fani, Melpomeni
Publication type:
Article
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study.
Published in:
EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01101-w
By:
- Rottenburger, Christof;
- Hentschel, Michael;
- Fürstner, Markus;
- McDougall, Lisa;
- Kottoros, Danijela;
- Kaul, Felix;
- Mansi, Rosalba;
- Fani, Melpomeni;
- Vija, A. Hans;
- Schibli, Roger;
- Geistlich, Susanne;
- Behe, Martin;
- Christ, Emanuel R.;
- Wild, Damian
Publication type:
Article
Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.
Published in:
Frontiers in Nuclear Medicine, 2024, p. 1, doi. 10.3389/fnume.2024.1481343
By:
- Bernabeu, Tais Basaco;
- Mansi, Rosalba;
- Del Pozzo, Luigi;
- Gaonkar, Raghuvir Haridas;
- McDougall, Lisa;
- Johayem, Anass;
- Blagoev, Milen;
- De Rose, Francesco;
- Jaafar-Thiel, Leila;
- Fani, Melpomeni
Publication type:
Article
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Published in:
Psychopharmacology, 2005, v. 179, n. 1, p. 303, doi. 10.1007/s00213-004-1982-8
By:
- Krystal, John H.;
- Abi-Saab, Walid;
- Perry, Edward;
- D'Souza, D. Cyril;
- Nianjin Liu;
- Gueorguieva, Ralitza;
- McDougall, Lisa;
- Hunsberger, Tracy;
- Belger, Aysenil;
- Levine, Louise;
- Breier, Alan
Publication type:
Article
61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
Published in:
Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267126
By:
- Basaco Bernabeu, Tais;
- Mansi, Rosalba;
- Del Pozzo, Luigi;
- Zanger, Sandra;
- Gaonkar, Raghuvir H.;
- McDougall, Lisa;
- De Rose, Francesco;
- Jaafar-Thiel, Leila;
- Herz, Michael;
- Eiber, Matthias;
- Ulaner, Gary A.;
- Weber, Wolfgang A.;
- Fani, Melpomeni
Publication type:
Article
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Published in:
Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266817
By:
- Eigler, Christopher;
- McDougall, Lisa;
- Bauman, Andreas;
- Bernhardt, Peter;
- Hentschel, Michael;
- Blackham, Kristine A.;
- Nicolas, Guillaume;
- Fani, Melpomeni;
- Wild, Damian;
- Cordier, Dominik
Publication type:
Article
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Published in:
Journal of Nuclear Medicine, 2024, v. 65, n. 4, p. 573, doi. 10.2967/jnumed.123.266817
By:
- Eigler, Christopher;
- McDougall, Lisa;
- Bauman, Andreas;
- Bernhardt, Peter;
- Hentschel, Michael;
- Blackham, Kristine A.;
- Nicolas, Guillaume;
- Fani, Melpomeni;
- Wild, Damian;
- Cordier, Dominik
Publication type:
Article
Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.
Published in:
Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.233031
By:
- Rottenburger, Christof;
- Nicolas, Guillaume P.;
- McDougall, Lisa;
- Kaul, Felix;
- Cachovan, Michal;
- Vija, A. Hans;
- Schibli, Roger;
- Geistlich, Susanne;
- Schumann, Anne;
- Rau, Tilman;
- Glatz, Katharina;
- Behe, Martin;
- Christ, Emanuel R.;
- Wild, Damian
Publication type:
Article
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
Published in:
Journal of Nuclear Medicine, 2017, v. 58, n. 9, p. 1435, doi. 10.2967/jnumed.117.191684
By:
- Nicolas, Guillaume P.;
- Mansi, Rosalba;
- McDougall, Lisa;
- Kaufmann, Jens;
- Bouterfa, Hakim;
- Wild, Damian;
- Fani, Melpomeni
Publication type:
Article
Small Stomates and Xylem Vessels Associated With Freeze Tolerance in Winter Barley.
Published in:
Journal of Agronomy & Crop Science, 2024, v. 210, n. 4, p. 1, doi. 10.1111/jac.12737
By:
- Liang, Xi;
- Hu, Gongshe;
- McDougall, Lisa;
- Werth, Jason;
- Yang, Rui;
- Yang, Jingya;
- Evans, Chris;
- Satterfield, Kathy
Publication type:
Article
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 8, p. 2517, doi. 10.1007/s00259-024-06641-w
By:
- Fricke, Julia;
- Westerbergh, Frida;
- McDougall, Lisa;
- Favaretto, Chiara;
- Christ, Emanuel;
- Nicolas, Guillaume P.;
- Geistlich, Susanne;
- Borgna, Francesca;
- Fani, Melpomeni;
- Bernhardt, Peter;
- van der Meulen, Nicholas P.;
- Müller, Cristina;
- Schibli, Roger;
- Wild, Damian
Publication type:
Article

Found: 11

SPECT Imaging of SST2-Expressing Tumors with 99m Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study.

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.

<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.

Cholecystokinin-2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.

Biodistribution, Pharmacokinetics, and Dosimetry of <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>111</sup>In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist <sup>177</sup>Lu-DOTATATE: The Mass Effect.

Small Stomates and Xylem Vessels Associated With Freeze Tolerance in Winter Barley.

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.